Startups
DMD Therapeutics is based in Seattle, although at present it is a virtual company, and, as its name suggests, is focused on developing therapeutics for DMD.
The Series A was led by GV, with participation from AtlasVenture, Takeda Ventures, Vertex Ventures HC, Amgen Ventures, Alexandria Venture Investments, and ShangPharma Group.
With headquarters located in San Diego, Calif. and Kalamazoo, Mich., Cirius Therapeutics is a clinical-stage pharmaceutical company focused on developing a treatment for NASH.
CARMA Therapeutics is based on technology from the Center for Cellular Immunotherapies at the University of Pennsylvania, and was spun out of the laboratory of Saar Gill, assistant professor of Hematology Oncology in the Perelman School of Medicine there.
Boragen is located in Research Triangle Park in Durham, N.C., and focuses on boron-based development of anti-bacterials and anti-fungicides for the agricultural industry.
BlueRock Therapeutics, which has locations in Toronto, NYC and Cambridge, Mass., rocketed to existence in December 2016 with $225M in venture funding to focus on regenerative medicine, using iPSC therapies.
Apostle, headquartered in Sunnyvale, Calif., hopes to file an IPO or establish other strong business collaborative routes in five years.
Based in Santa Clara, California, CBT Pharma was spun out of Crown Bioscience with four development-stage assets in the oncology space.
Tiny ITUS believes it is on track to develop a CAR-T treatment for solid tumors.
The financing was by Flagship Pioneering.
PRESS RELEASES